Phase II Study of Panitumumab in the Treatment of Carcinoid Syndrome.

Trial Profile

Phase II Study of Panitumumab in the Treatment of Carcinoid Syndrome.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2013

At a glance

  • Drugs Panitumumab (Primary)
  • Indications Carcinoid tumour; Malignant carcinoid syndrome
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 01 Jul 2013 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
    • 17 Jan 2013 Planned initiation date changed from 1 Jul 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
    • 09 Jul 2012 Planned End Date changed from 1 Sep 2014 to 1 Jul 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top